Harmony Biosciences Holdings, Inc. (HRMY)
Oxford Ledge is still expanding full research coverage of HRMY. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Harmony Biosciences develops rare neurological disease treatments, with FDA-approved narcolepsy medication WAKIX as its lead product.
SEC filings
- 8-K Shareholder vote results 2026-05-14
- 8-K Results of operations / financial condition; Regulation FD disclosure; Financial statements and exhibits 2026-05-07
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- 8-K Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-04-14
- DEF 14A Proxy statement for shareholder vote 2026-04-03
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for HRMY. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open HRMY in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.